Related Experiment Video
Updated: Jan 21, 2026

Environmental Screening of Aeromonas hydrophila, Mycobacterium spp., and Pseudocapillaria tomentosa in Zebrafish Systems
Published on: December 8, 2017
Molecular characteristics, pathogenicity and medication regimen of Aeromonas hydrophila isolated from common carp
Xian-Liang Zhao1,2, Zhao-Hui Jin2, Gui-Lan DI2
1College of Life Sciences, Henan Normal University, Xinxiang, Henan 453007, China.
Abstract:
Aeromonas hydrophila causes disease in fish known as Motile Aeromonas Septicemia (MAS), also named as bacterial hemorrhagic septicemia. In this study, a pathogenic A. hydrophila strain was isolated from common carp Cyprinus carpio L., which were suffering from severe hemorrhagic septicemia. According to the phylogenetic analysis derived from 16S rDNA sequence, the isolate formed a single branch in the A. hydrophila group, named AhHN1. Artificial infection results indicated that AhHN1 showed strong pathogenicity in C. carpio and the LD50 was 1.38 × 106 CFU/fish, the clinical symptoms and pathological features of infected fish were similar to those observed in natural infections. The antimicrobial susceptibility testing revealed that AhHN1 resistance to more than 13 kinds of antimicrobial agents. However, the AhHN1 strain exhibited an extremely sensitivity to enrofloxacin, the in vitro activities of enrofloxacin were subsequently investigated and drug selection window (MSW) was 0.0016-0.0125 µg/ml. Pharmacokinetics data showed that plasma concentration of enrofloxacin was 0.0016, 0.0148 and 0.0282 µg/ml at 24 hr after orally administered with 2.5, 5 and 10 mg/kg enrofloxacin. Moreover, dosing once a day of 2.5, 5 and 10 mg/kg enrofloxacin, which the relative protection ratio (RPS) was amounted to 33.3, 66.7, and 83.3%, respectively. Therefore, 5 mg/kg enrofloxacin was considered to be the rational regimen for controlling AhHN1 infection in C. carpio in the countries where the use of enrofloxacin is permitted in aquaculture. The aim of this study was to establish a scientific medication regimen for the prevention and therapy of the mutidrug-resistant A. hydrophila infection.
Insights
A new Aeromonas hydrophila strain (AhHN1) caused severe disease in common carp. Enrofloxacin effectively treated this multidrug-resistant fish pathogen, with a 5 mg/kg daily dose recommended for aquaculture.
Area of Science:
- Aquatic microbiology
- Fish pathology
- Antimicrobial resistance
Background:
- Aeromonas hydrophila causes Motile Aeromonas Septicemia (MAS) in fish.
- A pathogenic strain, AhHN1, was isolated from diseased common carp (Cyprinus carpio L.).
- This strain exhibited resistance to multiple antimicrobial agents.
Purpose of the Study:
- To characterize the pathogenic A. hydrophila strain AhHN1.
- To evaluate the efficacy of enrofloxacin against AhHN1 infection in C. carpio.
- To establish an optimal enrofloxacin treatment regimen for aquaculture.
Main Methods:
- Phylogenetic analysis using 16S rDNA sequencing to identify the isolate.
- Artificial infection experiments to determine pathogenicity (LD50).
- Antimicrobial susceptibility testing and in vitro enrofloxacin activity assessment.
- Pharmacokinetic studies and relative protection ratio (RPS) determination for enrofloxacin dosing.
Main Results:
- The isolate was identified as a pathogenic strain of A. hydrophila, named AhHN1, with an LD50 of 1.38 × 10^6 CFU/fish.
- AhHN1 demonstrated resistance to over 13 antimicrobial agents but was highly sensitive to enrofloxacin.
- A dosage of 5 mg/kg enrofloxacin administered once daily provided 66.7% relative protection in infected C. carpio.
Conclusions:
- Enrofloxacin is a viable treatment option for multidrug-resistant A. hydrophila infections in common carp.
- A regimen of 5 mg/kg enrofloxacin daily is recommended for controlling AhHN1 in aquaculture where permitted.
- This study provides a scientific basis for using enrofloxacin in treating MAS in C. carpio.
More Related Videos
06:15Evaluating Virulence and Pathogenesis of Aeromonas Infection in a Caenorhabditis elegans Model
Published on: December 20, 2018
10:21Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
Published on: September 20, 2024
Related Concept Videos
Common Ion Effect
Characteristics of Life
Drug Dosage Regimen: Overview
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Dosage Regimen: Individualization
Dosage Regimens: Partial Pharmacokinetic Parameters
Dosage Regimen: Multiple Oral Dosage